16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Differential Urinary Proteome Analysis for Predicting Prognosis in Type 2 Diabetes Patients with and without Renal Dysfunction

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Renal dysfunction, a major complication of type 2 diabetes, can be predicted from estimated glomerular filtration rate (eGFR) and protein markers such as albumin concentration. Urinary protein biomarkers may be used to monitor or predict patient status. Urine samples were selected from patients enrolled in the retrospective diabetic kidney disease (DKD) study, including 35 with good and 19 with poor prognosis. After removal of albumin and immunoglobulin, the remaining proteins were reduced, alkylated, digested, and analyzed qualitatively and quantitatively with a nano LC-MS platform. Each protein was identified, and its concentration normalized to that of creatinine. A prognostic model of DKD was formulated based on the adjusted quantities of each protein in the two groups. Of 1296 proteins identified in the 54 urine samples, 66 were differentially abundant in the two groups (area under the curve (AUC): p-value < 0.05), but none showed significantly better performance than albumin. To improve the predictive power by multivariate analysis, five proteins (ACP2, CTSA, GM2A, MUC1, and SPARCL1) were selected as significant by an AUC-based random forest method. The application of two classifiers—support vector machine and random forest—showed that the multivariate model performed better than univariate analysis of mucin-1 (AUC: 0.935 vs. 0.791) and albumin (AUC: 1.0 vs. 0.722). The urinary proteome can reflect kidney function directly and can predict the prognosis of patients with chronic kidney dysfunction. Classification based on five urinary proteins may better predict the prognosis of DKD patients than urinary albumin concentration or eGFR.

          Related collections

          Most cited references45

          • Record: found
          • Abstract: found
          • Article: not found

          A “Proteomic Ruler” for Protein Copy Number and Concentration Estimation without Spike-in Standards*

          Absolute protein quantification using mass spectrometry (MS)-based proteomics delivers protein concentrations or copy numbers per cell. Existing methodologies typically require a combination of isotope-labeled spike-in references, cell counting, and protein concentration measurements. Here we present a novel method that delivers similar quantitative results directly from deep eukaryotic proteome datasets without any additional experimental steps. We show that the MS signal of histones can be used as a “proteomic ruler” because it is proportional to the amount of DNA in the sample, which in turn depends on the number of cells. As a result, our proteomic ruler approach adds an absolute scale to the MS readout and allows estimation of the copy numbers of individual proteins per cell. We compare our protein quantifications with values derived via the use of stable isotope labeling by amino acids in cell culture and protein epitope signature tags in a method that combines spike-in protein fragment standards with precise isotope label quantification. The proteomic ruler approach yields quantitative readouts that are in remarkably good agreement with results from the precision method. We attribute this surprising result to the fact that the proteomic ruler approach omits error-prone steps such as cell counting or protein concentration measurements. The proteomic ruler approach is readily applicable to any deep eukaryotic proteome dataset—even in retrospective analysis—and we demonstrate its usefulness with a series of mouse organ proteomes.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Transcriptome Analysis of Human Diabetic Kidney Disease

            OBJECTIVE Diabetic kidney disease (DKD) is the single leading cause of kidney failure in the U.S., for which a cure has not yet been found. The aim of our study was to provide an unbiased catalog of gene-expression changes in human diabetic kidney biopsy samples. RESEARCH DESIGN AND METHODS Affymetrix expression arrays were used to identify differentially regulated transcripts in 44 microdissected human kidney samples. DKD samples were significant for their racial diversity and decreased glomerular filtration rate (~25–35 mL/min). Stringent statistical analysis, using the Benjamini-Hochberg corrected two-tailed t test, was used to identify differentially expressed transcripts in control and diseased glomeruli and tubuli. Two different web-based algorithms were used to define differentially regulated pathways. RESULTS We identified 1,700 differentially expressed probesets in DKD glomeruli and 1,831 in diabetic tubuli, and 330 probesets were commonly differentially expressed in both compartments. Pathway analysis highlighted the regulation of Ras homolog gene family member A, Cdc42, integrin, integrin-linked kinase, and vascular endothelial growth factor signaling in DKD glomeruli. The tubulointerstitial compartment showed strong enrichment for inflammation-related pathways. The canonical complement signaling pathway was determined to be statistically differentially regulated in both DKD glomeruli and tubuli and was associated with increased glomerulosclerosis even in a different set of DKD samples. CONCLUSIONS Our studies have cataloged gene-expression regulation and identified multiple novel genes and pathways that may play a role in the pathogenesis of DKD or could serve as biomarkers.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer

              This Opinion article focuses on the trends and progress being made in identifying protein biomarker signatures of clinical utility in cancer using, in particular, blood-based proteomics.
                Bookmark

                Author and article information

                Journal
                Int J Mol Sci
                Int J Mol Sci
                ijms
                International Journal of Molecular Sciences
                MDPI
                1422-0067
                14 June 2020
                June 2020
                : 21
                : 12
                : 4236
                Affiliations
                [1 ]Asan Institute for Life Sciences, Asan Medical Center, Seoul 05505, Korea; zaulim3@ 123456gmail.com (H.-S.A.); yujiyoung202@ 123456gmail.com (J.Y.)
                [2 ]Department of Internal Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Korea; bedaya@ 123456hanmail.net (J.H.K.); shsong0209@ 123456gmail.com (S.H.S.); drsskim7@ 123456gmail.com (S.S.K.)
                [3 ]Department of Biomedical Sciences, University of Ulsan College of Medicine, Seoul 05505, Korea; hkyo723@ 123456naver.com
                [4 ]Convergence Medicine Research Center, Asan Institute for Life Sciences, Seoul 05505, Korea; nature8309@ 123456gmail.com
                [5 ]Clinical Proteomics Core Laboratory, Convergence Medicine Research Center, Asan Medical Center, Seoul 05505, Korea
                [6 ]Bio-Medical Institute of Technology, Asan Medical Center, Seoul 05505, Korea
                Author notes
                [* ]Correspondence: injkim@ 123456pusan.ac.kr (I.J.K.); kkkon1@ 123456amc.seoul.kr (K.K.); Tel.: +82-51-240-7224 (I.J.K.); +82-2-1688-7575 (K.K.)
                [†]

                These authors contributed equally to this work.

                Author information
                https://orcid.org/0000-0003-2241-6536
                https://orcid.org/0000-0002-8218-6974
                https://orcid.org/0000-0002-9687-8357
                Article
                ijms-21-04236
                10.3390/ijms21124236
                7352871
                32545899
                d49e11f5-4c14-49f5-bceb-0f61c9a59961
                © 2020 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 03 April 2020
                : 12 June 2020
                Categories
                Article

                Molecular biology
                urine,diabetic kidney disease,kidney function,proteomics,mass spectrometry,statistical clinical model,machine learning

                Comments

                Comment on this article